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Purpose 
Central venous access devices (CVADs) are commonly employed in the 
management of cancer patients. While having several benefits they are associated 
with significant risks. We reviewed the incidence and risk factors for catheter-related 
thrombosis (CRT) in cancer patients with CVADs.  
Methods 
We performed a prospective observational cohort study of adult patients with cancer 
requiring a CVAD between January 1 2004 and June 29 2016. The rate of, and risk 
factors for the development of, symptomatic catheter-related thrombosis were 
evaluated. 
Results 
4920 central lines were inserted into 3130 patients. The incidence of CRT was 3.6%. 
CRT developed a median of 12 days following line insertion. PICCs were associated 
with the highest rates of CRT (HR 22.2, 95% CI 2.9-170.6). Older age groups 
developed CRT at lower rates (HR 0.57; 95%CI 0.39-0.84 for age 50-61 years, and 
HR 0.63; 95% CI 0.45-0.89 for age > 61 years) compared to age < 50 years. 
Increased CRT was seen in patients with prior CRT (HR 1.81; 95%CI 1.19-2.77). 
There was a trend to more for cancer subtype with a Khorana tumor score of 1 
compared to those with a score of 0 (HR 1.37, 95% CI 1.00-1.88). Hodgkin 
lymphoma, germ cell and oesophagus cancers had the highest CRT rates. Side of 
insertion was not associated with thrombosis risk (HR 0.77; 95% CI 0.57-1.05 
P=0.10). 
Conclusions 
Age <50, PICC lines and prior CRT were associated with highest CRT rate. Cancer 
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Central venous access devices (CVADs) are commonly used in cancer patients for 
the administration of chemotherapy, parenteral nutrition, blood products and 
antibiotics as well as enabling frequent blood sampling without the need for 
venepuncture. They are also often utilised for the collection and infusion of stem cell 
transplants. CVADs, however, carry significant risks including mechanical, infective 
and thrombotic complications1. Peripherally inserted central catheters (PICCs) are 
rising in popularity because they are inserted in the arm and avoid many of the 
mechanical complications associated with traditional central venous catheters (CVCs). 
They also facilitate the transition from inpatient to outpatient therapy2, can be inserted 
at the bedside by appropriately trained nurses and are associated with lower cost 3. 
Despite this perceived benefit, PICCs have significantly higher rates of catheter-
related thrombosis (CRT) than their centrally inserted counterparts. The incidence of 
symptomatic CRT in cancer patients varies between studies with a reported incidence 
in meta-analysis of 6.67%, with rates as low as 1.7% using long term skin tunnelled 
catheters4,5. When screening techniques are used to detect asymptomatic thrombosis, 
a higher incidence has been reported6.  
Aside from line type, several other risk factors for development of CRT have been 
evaluated. These include insertion site, catheter tip positioning, side of insertion, prior 
history of venous thrombosis, number of lumens, type of chemotherapy or prior 
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catheter-associated blood stream infection (CA-BSI)5,7,8. This has led to the 
recommendation that PICCs be avoided, particularly in the critically ill or those with 
cancer or, if a PICC is required, avoidance of tip location in the upper superior vena 
cava and avoidance of insertion into the left arm9. The concern regarding left sided 
insertion is primarily based on data using centrally placed catheters, rather than 
PICCs. More recent data investigating PICC lines only generally do not support 
increased incidence with left sided PICCs2,5. 
Certain types of cancer are associated with higher rates of venous thromboembolism 
which has led to the development and subsequent validation of risk scoring tools10 to 
determine the patients at highest risk of thrombotic events. The best validated is the 
Khorana score, which appraises the cancer subtype, body mass index and blood 
counts11,12, with higher scores being associated with a higher risk of thrombosis. In the 
Khorana score gastric and pancreatic cancers have the highest risk of thrombosis. 
Whether the type of cancer influences CRT is uncertain. 
We sought to review the incidence and risk factors for CRT in a large cohort of 
hematology and oncology patients in an Australian tertiary hospital. 
 
Methods 
Study setting and population 
This article is protected by copyright. All rights reserved.
 
This study was conducted in the Division of Cancer Services at the Princess Alexandra 
Hospital in Brisbane, Australia. This adult tertiary referral hospital includes medical 
oncology (excluding gynaecologic malignancy), haematology, radiation oncology and 
autologous but not allogeneic stem cell transplantation. All CVADs were inserted by 
trained operators within the Division of Radiology in a dedicated interventional facility 
using ultrasound guided venous puncture, as described elsewhere13. The study 
population comprised adult patients within the Division of Cancer Service, including 
hematology and oncology inpatients and outpatients, during the period 1 January 2004 
to 26 June 2016. All PICCs were inserted into the arm, avoiding the antecubital fossa, 
while all tunnelled and non-tunnelled CVCs were inserted into the internal jugular vein.  
Data were collected from the Division’s CVAD database, where prospective data on 
all CVAD insertions are stored. The database captures the following variables: name, 
unique patient identifier, date of birth, age, gender, patient diagnosis, CVAD number, 
date inserted, CVAD type, number of lumens, purpose of CVAD, insertion site or 
location, reason for removal, number of days the CVAD was inserted, as well as other 
catheter-related complications (such as infection, thrombosis and line fracture). 
Patient demographics and date of CVAD insertion were downloaded into the Cancer 
Services CVAD database from the Interventional Radiology Department each week. 
Data for each CVAD episode were updated by nurses trained to enter relevant 
information when the CVAD was removed in the clinical area. Regular data quality 
checks were performed to update missing variables. In addition, the Department of 
Vascular Imaging was contacted for all ultrasound imaging showing thrombosis over 
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the study period, which was cross-checked with the CVAD database to ensure all 
episodes of CRT were captured. The study was approved by the Metro South Human 
Research Ethics Committee.  
 
Definitions 
Catheter-related thrombosis was defined as thrombus occurring within the same 
vessel as a CVAD as detected using duplex ultrasonography, either while the CVAD 
was in situ or within one week of CVAD removal. No routine surveillance scanning was 
performed, thus imaging was performed on symptomatic patients only within either the 
diagnostic imaging department within the Division of Radiology or a dedicated vascular 
imaging suite within the Department of Vascular Medicine.  
For the purposes of this study, hematologic malignancies were classified as ‘intensive 
hematology’ and ‘other hematology’ based on intensity of therapy. Intense regimens 
included those for the treatment of acute leukemias and high-grade lymphomas (7+3, 
HiDAC, FLAG, HyperCVAD) or autologous stem cell transplantation. Cancer types 
were assessed as very high, high or standard risk, based on the previously developed 
Khorana risk scoring system11,12, whereby patients with either gastric or pancreatic 
carcinoma were given a score of 2, while lung, gynaecologic, and non-prostate 
genitourinary cancers or lymphomas were scored 1. Other malignancies were 
assigned a score of zero. When subsequently referred to in this paper, the term 
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Khorana score refers specifically to the tumour subtype given to these various cancer 
subtypes as detailed in the Khorana risk scoring system. 
 
Statistical analysis 
The study population was reported with descriptive statistics. The unit of analysis 
was a central line within a patient and the primary outcome was the number of line 
days until development of a symptomatic catheter-related thrombus. In the cases 
where the lines were inserted and removed on the same days, its number of line day 
was defined as 0.5 day to account for the period of line insertion less than one day. 
Incidence probability curves were described using non-parametric estimates of 
cumulative incidence function (CIF) with competing risk model, where other reasons 
for line removal are considered to be competing risks. 
Association between risk of CRT and patient or catheter related factors were 
examined using Cox regression model and competing risk model. As similar results 
were obtained from both models, Cox regression analysis results are presented. A 
multivariable model was fitted using all variables significant in the univariable 
analysis at the 20 percent level. The variables at the least significant level were 
sequentially excluded on the basis of Wald’s statistics until all remaining variables in 
the model had p-values below 0.05.  
Subgroup analysis was performed for CRT on the patients with PICC lines. 
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Robust covariance matrix was used to account for clustering of multiple lines within a 
patient. The proportional hazard assumption was checked for all variables included 
in the models. P-values were not adjusted for multiple testing. Analyses were 
performed using STATA 13.1 (StataCorp, TX). 
Results 
Baseline characteristics 
A total of 4920 central lines were inserted into 3130 patients between January 1, 
2004 and June 29, 2016 and included in the analysis.  The baseline characteristics 
of the study population and central venous catheters are summarised in Table 1. The 
study population included cancer patients aged 15 to 92 years (median 56 years). 
2068 (66.1%) patients had a single line and 1062 (33.9%) patients had multiple lines 
inserted over the course of treatment (range 2-10). 
The majority of lines were PICCs (72.4%) followed by non-tunnelled (12.9%) and 
tunnelled central venous catheters (10.6%) and implantable ports (4.1%). The 
number of line days per inserted line ranged from <1 to 2551 days, with a median of 
35 days. Median (IQR) line days for PICCs was 43 (20-88), tunnelled catheters 22 
(15-36), non-tunnelled catheters 4 (2-7) and implantable ports 488 (192-1025). Fifty 
four percent of lines were inserted into the right side. Approximately half (49.1%) the 
patients had a hematologic malignancy. The remainder were various solid tumours. 
The indication for line insertion was primarily administration of chemotherapy 
(78.1%), followed by stem cell collection (10.8%) and stem cell reinfusion (6.7%).  A 
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total of 224 (4.6%) lines were lost to follow up due to patient transfer to another 
facility.  
A total of 177 (3.6%) lines developed CRT. The rate of CRT per 1000-line days was 
0.45. In the lines in which CRT developed, it did so at a median of 12 days (range 1-
266 days), with 75% occurring within the first 26 days and 95% occurring within 104 
days of insertion (Figure 1). Lines were removed due to thrombosis in 145 (2.9%) 
cases. 176 (99.4%) of CRT events occurred in patients with PICCs, with only 1 event 
occurring in implantable port group and none in tunnelled (n=521) or non-tunnelled 
(n=634) CVADs. 
Analysis of CRT 
The results of univariable and multivariable Cox regression analyses of CRT are 
provided in Table 2. In multivariable analysis patients with PICC lines had the greatest 
risk of CRT with the hazard rate 22.2 times (95% CI 12.9-170.6) higher than implanted 
ports. There were no episodes of CRT associated with tunnelled or non-tunnelled 
centrally-inserted lines. Older age groups (50-61 years old and > 61 years old) 
developed CRT at lower rates (HR 0.57, 95%CI 0.39-0.84 and HR 0.63, 95% CI: 0.45-
0.89 respectively) compared to the youngest age group (< 50 years old). When age 
(years) was fitted into the model in place of age group, there was trend that the hazard 
rate reduced with an increase in patient’s age (HR 0.99, 95%CI 0.91-1.00, p=0.031). 
There was also evidence that greater number of prior CRT was associated with 
increased risk of CRT (HR 1.81, 95%CI 1.19-2.77, p=0.006, Figures 2 a-c).  
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The tumour subtype (defined by Khorana score) was not identified as a potential 
predictor of CRT. However, patients with Khorana tumour score of 1 had an increased 
risk of CRT compared to those with Khorana tumour score of 0 when controlling for 
line type, prior CRT and age group (HR 1.37, 95% CI: 1.00-1.88) (Figure 2d). A further 
descriptive analysis of CRT incidence across different cancer subtypes showed that 
patients with germ cell tumours and Hodgkin lymphoma (Khorana score 1) had higher 
rates of CRT (1.81 and 0.9 per 1000 line days respectively) (Table 3). Oesophageal 
carcinoma (Khorana score 0) also had a higher rate of CRT, 1.21 per 1000-line days 
while myeloma had the lowest rate (no events).  
Number of lumens, side of insertion and gender were found to be confounded by line 
type and not found to be significantly associated with risk of CRT in multivariable 
analysis. There was no difference in incidence rates of CRT between lymphoid and 
myeloid hematologic malignancies relative to solid tumours (HR 0.95; 95% CI 0.67-
1.34, HR 0.77; 95% CI 0.45-1.34 respectively; P=0.66).  
Secondary analysis of CRT in PICC lines 
We repeated the analysis specifically investigating PICC lines. A total of 3564 (72.2%) 
lines were inserted. The median line insertion duration was 43 (IQR 20-88) days with 
a thrombosis rate 4.9% (0.75 per 1000-line days). Age <50 and number of prior CRT 
events remained statistically significant predictors of CRT. There was no evidence of 
association between risk of CRT and insertion side, Khorana tumour score, gender or 
disease category.  
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When the analysis was also performed using the competing risk model, features found 
to be significant in the Cox analyses retained their significance (data not shown). 
Discussion 
CRT is a not infrequent occurrence in patients with cancer. In our study of almost 5000 
lines in 3130 patients, CRT incidence was 3.6%. In a meta-analysis of over 25000 
patients, the rate of CRT within the subgroup of 3430 cancer patients was 6.67%5. Our 
observed lower incidence may be due, in part to our method of insertion, with all being 
inserted using ultrasound guided insertion and fluoroscopic confirmation of tip location 
in a dedicated interventional radiology facility. Similar to these studies, we also 
employed imaging of symptomatic patients, rather than routine screening. Our data 
are also consistent with the published literature in that, when compared to other 
CVADs, we found the highest incidence of CRT related to PICCs, where the overall 
incidence of CRT was 4.9%.  
The literature is conflicting with regard to insertion side and risk of thrombosis. In 
accordance with the international guidelines published by Debourdeau et al14, 
avoidance of the left side is suggested, based on evidence from old studies using only 
centrally inserted CVADs15-17. The results of our large study are consistent with other 
reports which investigated CRT with PICCs and demonstrated no significant difference 
based on laterality of insertion6,8,18,19. Thus, it appears reasonable to conclude that 
with respect to PICC lines, the side of insertion is not important. We were unable to 
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investigate the influence of laterality of insertion on centrally inserted lines as only 2 
patients developed CRT outside of the PICC group (0.14%). 
The median duration of line days for tunnelled lines and PICC lines was 22 (IQR 15-
36) and 43 (IQR 20-88) days respectively, both longer than the median time to 
development of CRT of 12 (IQR 7-26) days. Implantable ports remained in situ for a 
median of 488 (IQR 192-1025) days. With all but one CRT event occurring in patients 
with PICCs, clearly the risk of CRT is relatively unique to PICC lines. The reasons for 
such a low incidence in the internal jugular route most likely relate to a combination of 
factors, including a much shorter intravascular course, larger luminal diameter of the 
punctured vein and universal insertion in an interventional radiology facility plus 
fluoroscopic confirmation of tip location. The lack of CRT events in the non-tunnelled 
group is most likely due to small numbers of line days (median 4, IQR 2-7 days) as 
these lines are primarily used for stem cell collection, infusion or haemodialysis in our 
institution. 
Increased rates of CRT have been seen in patients with a history of DVT8,19. Although 
our database did not record this information, it demonstrated a trend toward an 
increased rate of CRT in those patients with a previous CRT episode. We also 
evaluated the influence of the previously described Khorana scoring system11. Our 
data showed no evidence of a significant association specifically between the tumour 
score and the CRT rate. There was a trend that patients with a Khorana score of 1 
had higher risk than those with a Khorana score of 0 (HR 1.37, 95% CI: 1.00-1.88). It 
should be noted that we did not consider other factors (e.g. BMI, haemoglobin level) 
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in the original Khorana model, and that the Khorana model was designed for 
assessment of overall VTE risk in cancer patients rather than CRT, or within specific 
tumour subtypes. Additionally, recent studies in specific types of cancer have called 
into question the discriminatory power of this model 20, 21.   
In our study the rate of CRT was the highest in patients receiving treatment for germ 
cell tumours. High rates of VTE have previously been reported in these patients, with 
up to 40% of patients having a deep venous thrombosis22 while receiving platinum-
based therapy. A previous meta-analysis concluded that brain and pancreas tumours 
have the highest risk of VTE23. There were very few brain tumour patients in our 
dataset, most likely reflecting the lack of necessity for long-term intravenous access in 
this patient group.  
In the broader context of all CRT (not specific to cancer), a systematic review by Leung 
and colleagues reported a weak influence of patient age, with only 3 of 17 reviewed 
studies showing an association. These studies all demonstrated older age having a 
positive association with CRT24. Older patients are more likely to have comorbid 
illnesses which require anticoagulant or antiplatelet agents. It has been demonstrated 
in numerous randomised controlled trials that prophylaxis with low molecular weight 
heparin, fixed or variable dose warfarin do not protect from development of 
symptomatic CRT in cancer patients25, suggesting baseline anticoagulation is unlikely 
the explanation. The role of novel oral anticoagulant agents and antiplatelet drugs in 
CRT prevention is less clear and warrants further prospective exploration. 
Interestingly, our data indicate that patient age may be a potential predictor of CRT, 
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with the highest incidence in patients under the age of 50. The reasons for an increase 
in CRT in younger patients at our centre are unclear but may be related to different 
cancer types seen in these patients. Further studies are needed to elucidate the 
association between young age and the risk of CRT.  
One weakness of this study relates to the reporting of CRT, being limited to those 
detected in our institution. Patients who had imaging performed externally might not 
have been detected in this study, however we feel the impact of this is likely to be 
small, based on the way patients are followed up and encouraged to return to the 
treating hospital if there are problems or concerns. Based on this, the overall incidence 
of CRT could be under-reported in these data. There is also a risk of confounding as 
certain line types are more likely to be inserted into patients with specific malignancies. 
While residual confounding cannot be completely accounted for, we have attempted 
to minimise this risk through using a multivariate analysis. When we looked specifically 
at AML patients (due to the large numbers of tunnelled CVL and PICC lines), CRT was 
demonstrated exclusively within those with PICCs.  
This study does have several strengths. The central line data were collected 
prospectively into a purpose-built database. To our knowledge, this is the largest 
published single-centre study assessing the risk of CRT among patients with cancer, 
across all types of lines. In addition, this is the first attempt to investigate the rates of 
CRT in patients with different cancer subtypes. 
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The decision about what form of CVAD to use in the cancer patient is a complex one. 
PICCs are a popular choice based primarily on convenience, cost and ease of access. 
The decision to insert a PICC must include consideration of the higher risk of 
thrombosis, particularly in those who have experienced CRT previously, younger 
patients or those with higher risk cancers.  
In conclusion, we have identified that in patients with cancer PICC lines are associated 
with the highest risk of CRT. CRT is extremely uncommon in centrally inserted 
tunnelled and non-tunnelled lines when internal jugular access is utilised under 
ultrasound guidance in a dedicated interventional radiology facility. Patients are at 
increased risk of CRT if they are aged <50 years or have a prior history of thrombosis 
however tumour risk based on those in the Khorana model and insertion side were not 
significant predictors of thrombosis. 
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Figure 1.  Cumulative probability of catheter-related thrombosis estimated by competing 
risks model. Solid lines represent cumulative incidence function. Hatched 
lines represent 95% confidence interval. 
Figure 2. Cumulative probability of catheter-related thrombosis according to; a) line 
type; b) patient age group; c) presence of prior thrombosis; d) Khorana risk 
score (2 = pancreas, stomach, 1= lung, lymphoma, genitourinary (excluding 
prostate), gynaecologic, 0=all other cancers).   
This article is protected by copyright. All rights reserved.
 
Table 1. Baseline Characteristics 
 
Variables  Total (n=4920) 
Age (years), median (IQR) 56 (46-65) 
Gender  
   Female 2158 (43.9%) 
   Male 2762 (56.1%) 
No. of prior lines  
   0 3130 (63.6%) 
   1 1062 (21.6%) 
   2 430 (8.7%) 
   ≥3 398 (6.1%) 
No. of prior CRT  
   0 4741 (96.4%) 
   1 167 (3.4%) 
   2 11 (0.2%) 
   3 1 (<0.1%) 
Line type  
   Tunnelled (Hickman) 470 (9.6%) 
   Tunnelled (Apheresis Hickman) 51 (1.0) 
   Non-tunnelled (Medcomp) 634 (12.9%) 
   PICC 3564 (72.4%) 
   Implantable port (Port-a-cath) 201 (4.1%) 
Side of insertion  
   Left 2267 (46.1%) 
   Right 2653 (53.9%) 
Insertion site  
   Jugular 1320 (26.8%) 
   Arm 3576 (72.7%) 
   Femoral 24 (0.5%) 
Lumens  
   Single 243 (4.9%) 
   Double  4660 (94.7%) 
   Triple 17 (0.3%) 
Patient Diagnosis:  
Risk groups (Khorana tumour score) 
(n=4908) 
 
   0 3297 (67.2%) 
   1 1411 (28.7%) 
   2 200 (4.1%) 
Treatment regimen  
   Intensive haematology 2197 (44.7%) 
   Other haematology 217 (44.4%) 
   Other cancers 2506 (50.9%)  
Patient Diagnosis  
   Myeloid malignancies 601 (12.2%) 
   Lymphoid malignancies 1813 (36.8%) 
   Other cancers 2506 (50.9%) 
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Purpose of line insertion  
   Chemotherapy 3893 (77.2) 
   Blood Products 24 (0.5) 
   IV antibiotics 193 (3.8) 
   Stem Cell Collection 534 (10.6) 
   Stem Cell Transplant 328 (6.5) 
   Therapeutic Apheresis 45 (0.9) 
   Dialysis 26 (0.5) 
CRT, catheter-related thrombosis; PICC, peripherally inserted 
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Table 2. Cox regression analysis of cancer-related thrombosis. 
  
Univariable Analysis Multivariable analysis  
HR (95% CI) p-value HR (95% CI) p-value 























   Female 1.00 
   
   Male 1.34 (0.97-1.85) 
   
No. of prior line 0.90 (0.76-1.08) 0.26 
  


























   Left 1.00 
   
   Right 0.77 (0.57-1.05) 





   Single  1.00 
   
   Multiple 2.69 (1.07-6.77) 
   




   0 1.00 
   
   1 1.47 (1.06-2.05) 
   
   2 0.95 (0.44-2.05) 





   Intensive hematology 0.84 (0.60-1.17) 
   
   Other hematology 1.43 (0.73-2.80) 
   
   Other cancers 1.00 





   Myeloid malignancies 0.77 (0.45-1.34) 
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   Lymphoid malignancies 0.95 (0.67-1.34) 
   
   Other cancers 1.00 
   
* 95% CI was not determined due to no events in the categories. 
  CRT, catheter-related thrombosis; PICC, peripherally inserted central venous catheter;    
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Table 3. CRT rates (percentage and events per 1000 line-days) by cancer subtypes 
Cancer subtype % (No. CRT/No. 
catheter) 
CRT events per 
1000 line days 
AML 3.0% (14/472) 0.61 
APML 3.2% (3/93) 0.61 
ALL 3.7% (5/137) 0.54 
NHL 3.6% (36/1002) 0.69 
Myeloma 0% (0/457) 0 
Breast 4.4% (19/430) 0.17 
Colon/Rectal 3.9% (32/819) 0.42 
Gastric 4.4% (6/136) 0.57 
Sarcoma 1.7% (2/120) 0.14 
Lung 3.6% (5/141) 0.29 
Oesophagus 6.0% (23/384) 1.21 
Pancreas 1.6% (1/64) 0.20 
Hodgkin Lymphoma 6.3% (9/142) 0.90 
Germ cell 6.1% (7/115) 1.81 
Others 3.7% (15/408) 0.65 
Total 3.6% (177/4920) 0.45 
AML, Acute myeloid leukemia; APML, Acute promyelocytic leukemia; ALL, Acute 
lymphoblastic leukemia; NHL, non-Hodgkins lymphoma; CRT, catheter-related thrombosis 
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